Il piu grande centro europeo di ricerca oggi festeggia l'anniversario del Nobel di Rubbia e Van der Meer. Cern, vent'anni guardando al futuro Ora la sfida si gioca sull'acceleratore di particelle pronto per il 2007, che provera a svelare i segreti della materia

Autor: Durante, E

"CERN, vent'anni guardando al futuro Ora la sfida si gioca sull'acceleratore di particelle pronto per il 2007, che provera a svelare i segreti della materia" [CERN, twenty years of looking towards the future. The present challenge is the particle acc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od________65::fad54614ec207707faa298b9872ed0cf
http://cds.cern.ch/record/718410

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2years

Autor: Anne M. Uyterlinde, Clemens F.M. Prinsen, Harry J.M. Groen, Susanne E van der Meer, Anne S. Bolijn, Hans Berkhof, Harry J. de Koning, A. Jasmijn Hubers, Renske D.M. Steenbergen, Birgit I. Witte, Mandy Wouters, Daniëlle A.M. Heideman, Peter J.F. Snijders, Erik Thunnissen, Sylvia Duin, Egbert F. Smit

Publikováno v: Journal of Clinical Pathology, 70(3), 250-254. BMJ Publishing Group
Journal of Clinical Pathology, 70(3), 250-254. BMJ PUBLISHING GROUP
Journal of Clinical Pathology. BMJ Publishing Group
Hubers, A J, Heideman, D A M, Duin, S, Witte, B I, de Koning, H J, Groen, H J M, Prinsen, C F M, Bolijn, A S, Wouters, M, van der Meer, S E, Steenbergen, R D M, Snijders, P J F, Uyterlinde, A, Berkhof, H, Smit, E F & Thunnissen, E 2016, ' DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial : argument for maximum screening interval of 2 years ', Journal of Clinical Pathology . https://doi.org/10.1136/jclinpath-2016-203734

AIMS: Lung cancer is the major contributor to cancer mortality due to metastasised disease at time of presentation. The current study investigated DNA hypermethylation of biomarkers RASSF1A, APC, cytoglobin, 3OST2, FAM19A4, PHACTR3 and PRDM14 in sput

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7729a9a7bca4fb579443bbf94ae1e493
https://doi.org/10.1136/jclinpath-2016-203734

Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis

Autor: J A Dijkstra, Jan-Willem C. Alffenaar, M E van der Meer, J F Borjas Howard, R. van Altena, D. van Soolingen, T S van der Werf, Jos G. W. Kosterink

Publikováno v: Antimicrobial Agents and Chemotherapy, 61, e01400-16-e01400-16
Antimicrobial Agents and Chemotherapy, 61(3). American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 61(3):UNSP e01400-16. AMER SOC MICROBIOLOGY
van Altena, R, Dijkstra, J A, van der Meer, M E, Borjas Howard, J F, Kosterink, J G W, van Soolingen, D, van der Werf, T S & Alffenaar, J W C 2017, ' Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis ', Antimicrobial Agents and Chemotherapy, vol. 61, no. 3 . https://doi.org/10.1128/AAC.01400-16
Antimicrobial Agents and Chemotherapy, 61, 3, pp. e01400-16-e01400-16

Hearing loss and nephrotoxicity are associated with prolonged treatment duration and higher dosage of amikacin and kanamycin. In our tuberculosis center, we used therapeutic drug monitoring (TDM) targeting preset pharmacokinetic/pharmacodynamic (PK/P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bdac79b0c4f8853428eac4d08e28050
http://hdl.handle.net/2066/170279